ATM and breast cancer: Four patients with BC were enrolled with preliminary data demonstrating that the administration of elimusertib via oral treatment is well tolerated with antitumor efficacy in patients with advanced solid tumors, especially those with ATM deleterious mutations and/or a loss of ATM protein.